A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment

Leukemia

Volumn 22, Issue 4, 2008, Pages 856-858

  Schnittger, Susanne ^a   Bacher, U ^b   Kern, W ^a   Haferlach, T ^a   Hertenstein, B ^c   Haferlach, C ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c KLINIKUM BREMEN MITTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB; THREONINE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER RESISTANCE; CASE REPORT; CHROMOSOME 22; CHROMOSOME BANDING PATTERN; CHROMOSOME DELETION; CHROMOSOME INSERTION; CHRONIC MYELOID LEUKEMIA; COLON PERFORATION; COLON SURGERY; DEATH; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMERGENCY SURGERY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; KARYOTYPE 46,XY; LETTER; LEUKEMIA REMISSION; LEUKOCYTOSIS; MALE; MUCOSAL DISEASE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TETRASOMY; TRISOMY;

EID: 42349109959     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404949     Document Type: Letter

References (10)

1. Hochhaus A, Reiter A, Skladny H, Melo JV, Sick C, Berger U et al. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 1996; 88: 2236-2240.
2. Colla S, Sammarelli G, Voltolini S, Crugnola M, Sebastio P, Giulipni N. e6a2 BCR-ABL transcript in chronic myeloid leukemia: Is it associated with aggressive disease? Haematologica 2004; 89: 611-613.
3. Popovici C, Cailleres S, David M, Lafage-Pochitaloff M, Sainty D, Mozziconacci MJ. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to imatinib. Leuk Lymphoma 2005; 46: 1375-1377.
4. Quentmeier H, Cools J, Macleod RA, Marynen P, Uphoff CC, Drexler HG. e6-a2 BCR-ABL1 fusion in T-cell acute lymphoblastic leukemia. Leukemia 2005; 19: 295-296.
5. Maurer J, Janssen JW, Thiel E, van DJ, Ludwig WD, Aydemir U et al. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet 1991; 337: 1055-1058.
6. Gregoire MJ, Latger-Cannard V, Staal A, Bologna S, Leotard B, Rault JP et al. Identification of an acute basophilic leukaemia carrying a rare e6a2 BCR-ABL transcript. Acta Haematol 2006; 116: 216-218.
7. Roti G, La SR, Gorello P, Gottardi E, Crescenzi B, Martelli MF et al e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia. Haematologica 2005; 90 1139-1141.
8. Hayette S, Tigaud I, Thomas X, French M, Perrin MC, Nicolini F et al Identification of a rare e6a2 BCR-ABL fusion gene during the disease progression of chronic myelomonocytic leukemia: A case report. Leukemia 2004; 18: 1735-1736.
9. Schultheis B, Wang L, Clark RE, Melo JV. BCR-ABL with arr e6a2 fusion in a CML patient diagnosed in blast crisis. Leukemia 2003; 17: 2054-2055.
10. Kreil S, Pfirrmann M, Haferlach C, Waghorn K, Chase A, Hehlmann R et al. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 2005; 110: 1283-1290.